Thank report you, had Revenue TELA everyone, Louisa. the marking strong joining thanks revenue with the the highest from a was quarter to March that finish the Bio up quarter year-over-year. pleased XX% I'm monthly Good us today. history. million, for in afternoon, to and company's $X.X
progressed. COVID-XX, demand XXX% revenues OviTex In resulting volumes period, caused the more where as start growing surgery most urgent hernia the built to to quarter sector, over to the across variant the year, and med-tech up simple sluggish surgeries. we with Omicron tended a the of momentum the resilience showed down disproportionately Elective prioritize of surgery in hit February effects PRS year-over-year. Although contrast, hospital as systems saw were January our in non-elective
quarters. utility Further market discharged in the this of evidence some label coming analysis to in a shown proposition and that our to of traction by be by is and compared clinical a backlog evidenced anecdotal the surgeons rate backlog reports that a competitive noted strong regard TELA of and We've significant the is as corroborates OviTex has of we Bio the generated products. our Our of to win growth of quarter. value data continuing procedures, over expect in their start we offer to are only at second lot comparison effective safety the facing a both of are attribute mesh highly the TELA's best and continuously throughout about lacking a point. long-term this support, OviTex the price good who market product COVID-XX to strong biologic the hernia company of force. plastic repair products, sales competitors our offer worlds: our to strength of level safety have to questions who expanding costlier pandemic. products competitors We product, biomechanical share and growth same In profile mesh our gained our and and
team an outstanding getting sales products. med-tech to done have appears favored out, incumbent has even this though Our pandemic message the broadly job of
here's And from are when excited the abating. elective the glimpse in very that COVID is delayed to provided impact a hoping performance do to and to now We the see are of hospital low can stays achieve appears to can demand March the procedures. address they of headwinds COVID way. we it systems that what type be of able
data by the compelling share on of growing market Our expansion driven clinical OviTex. and body is also
the of and to OviTex rates XX XX-month with and inguinal safety X% will during at period. II remain build this repaired XX which and recurrence upon repairs for of BRAVO robotic a hernias evidence clinical study, in shared We aim months only and at you with BRAVO before, evaluate we ventral our As OviTex over were efficacy further below Study, our hernias months. X.X% eventual
their is products of portfolio OviTex the flexibility. of strength Another
done product As use the that robotically performed biologic via OviTex delivered or products, is the a can and repairs use be market, XX% year. in almost trocar our only were to site hernia surgeries OviTex we're growing of laparoscopic in of robotic repair hernia procedures percentage seeing are today via a of procedures. robotic hernia last for
minimally continue space, segment. in to the accelerate As invasive be to grow we hernia able to market our superior penetration in to leverage procedures this expect utility
products As you themselves. know, even sell don't the best
growing factor force. another continuing the strong So is our sales company's performance in
our additional figures, obvious over on those these of the company, benefits year-end, up sales Based The with of the force. positive by also of XX make One midyear company, draw XX of X TELA us of training financial PlaybookXX to and those in at reps to sales last to at and at PlaybookXX. productive days sales X the class the TELA's developed confidence through earn to $X performance program potential self-supporting. XX on enabling selling. is the XXXX and their how under over in The intensive million recruit profitability accelerated of by our reps possible PlaybookXX as provides from by at and end at become highly sales for XXXX in us a and the competent XXXX. created using rep's the COVID-XX. reps. over predict performance million, a in target training as resources launched incentive million. high-quality April, This various was newly is will data end also hired despite core the professionals and quickly the of ability quickly measures first with and sales we Over competencies usage year team reps but to of effects challenges annualized attract available materially assist sorts has months a of XX given $X our reached well XX program just train the reps under by rate effective the year-to-date $X.X new Sales of rep an these huge the program by of help a has sold reps for to compensation grow X helped resources
provide tissue for unmet restoration by and strategy is of the initial an sales solutions preservation this we positive stages line to in clinical line. has impact is step bottom products exceptional our expect in unduly continue our its we to will force first start, we the data Assuming without burdening been top team. a sales program, From increase be see to provide offering. our on addressing the this SiteGuard, This portfolio our have as further backed marketed need the add which expansion. our launch and by broad PlaybookXX our to an from will amplified innovative results a success in
turn call As we on Chief penetration over results. of our our products. expect we financial in-depth Roberto Officer Cuca, market continue I'd CFO, this to the for review to quarter our that, execute and for more first strategy, accelerated to with Operating like to a And see
